Actively Recruiting
Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Led by iOMEDICO AG · Updated on 2026-01-28
2950
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are establishing a national, prospective, longitudinal, multicenter registry platform in Germany to collect consistent data on patients with hematological malignancies. This observational study aims to document patient characteristics, molecular diagnostics, treatments, and disease progression, while also gathering patient-reported outcomes and creating a decentralized biobank. The goal is to understand treatment patterns, evaluate new therapies in routine care, and identify areas for improvement in patient management. Participants include patients with various types of non-Hodgkin lymphomas such as Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström's Macroglobulinemia. All receive systemic treatment as chosen by their physicians according to routine care standards. Data collection includes treatments like systemic therapies, radiotherapies, and surgeries, with observation extending up to five years for treatment course and outcomes. During the study, researchers collect detailed information on patient health status, treatments received, and clinical outcomes. Health-related quality of life is evaluated up to one year through patient surveys, including disease-specific quality of life assessments for certain lymphoma types. The study monitors best response, progression-free survival, and overall survival over five years, providing comprehensive insights into treatment realities and patient experiences in routine care.
CONDITIONS
Brief Title
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Confirmed diagnosis of the respective non-Hodgkin lymphoma
- Signed written informed consent if patient is alive
- For patients participating in the patient-reported outcome survey: informed consent prior to or at start of respective line of treatment
- For patients not participating in the patient-reported outcome survey: informed consent within eight weeks after start of respective line of treatment
You will not qualify if you...
- No systemic therapy for the respective lymphoid malignancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants who undergo routine care are observed. Data on systemic treatments, radiotherapies, surgeries, and clinical outcomes are collected during routine care.
Visits occur as per routine clinical care schedules
Duration - Up to 1 year
Health-related quality of life and disease-specific quality of life are evaluated for up to one year through patient-reported outcomes.
Assessments may occur periodically during the first year
Trial Site Locations
Total: 1 location
1
Praxis für Interdisziplinäre Hämatologie und Onkologie
Freiburg im Breisgau, Germany
Actively Recruiting
Research Team
M
Martina Jänicke, Dr.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here